Why Reliance Life Sciences could be the next big thing in India’s biotechnology space
The ‘Business Today’- discusses the growth and future prospects of Reliance Life Sciences (RLS) in India’s biotechnology sector. After twenty years of development, RLS is now venturing into new segments and investing in a new manufacturing campus. The company aims to address unmet medical needs in rare genetic diseases, shifting from producing life-saving drugs for intensive and critical care patients.
The new facility, located in Dindori, Maharashtra, is a fully integrated second manufacturing campus expected to be ready in a year. With an investment of Rs 4,400 crore, it will focus on manufacturing plasma proteins, biosimilars, small molecule oncology products, vaccines, gene therapy, and mRNA products. The move towards gene therapy and mRNA products indicates the company’s ambition to adopt cutting-edge technologies.
RLS has steadily nurtured its research and manufacturing capabilities, diversifying its presence across segments. It currently boasts a portfolio of 43 products and employs 1,300 people. The biopharmaceuticals segment, which RLS is part of, is experiencing rapid growth at 25% annually, driving the company’s bet on higher volumes.
Mukesh Ambani, Chairman and Managing Director of Reliance Industries, expresses optimism about RLS’s future and its initiatives in vaccines, peptides, gene and cell therapies, mRNA, and oligonucleotides. The company aims to shift its focus from treating patients in hospitals to addressing rare genetic diseases and disorders.
Overall, the ‘BT’ highlights RLS as a promising player in India’s biotechnology space, with strategic investments and a diversified approach that positions it for future success in the growing market.
#Biotechnology #MedicalInnovation #RareDiseases #GeneTherapy #CuttingEdgeScience